|1.||Aurisicchio, Luigi: 4 articles (08/2010 - 10/2009)|
|2.||Ciliberto, Gennaro: 4 articles (08/2010 - 10/2009)|
|3.||La Monica, Nicola: 4 articles (08/2010 - 10/2009)|
|4.||Peruzzi, Daniela: 4 articles (08/2010 - 10/2009)|
|5.||Cuzzocrea, Salvatore: 4 articles (08/2009 - 03/2003)|
|6.||Mazzon, Emanuela: 4 articles (08/2009 - 03/2003)|
|7.||Mesiti, Giuseppe: 3 articles (08/2010 - 10/2009)|
|8.||Bucolo, Claudio: 3 articles (08/2009 - 03/2003)|
|9.||Conforti, Antonella: 2 articles (08/2010 - 04/2010)|
|10.||Scarselli, Elisa: 2 articles (08/2010 - 10/2009)|
04/01/2006 - "Intraperitonal injection of cloricromene (10 mg/kg daily for 8 days) significantly decreased all of the parameters of inflammation as described above. "
12/01/2000 - "7. This study provides the first evidence that cloricromene, a coumarine derivative, attenuates the degree of chronic inflammation and tissue damage associated with collagen-induced arthritis in the rat."
06/01/2007 - "These data, along with the previously published potency data for cloricromene, suggest that cloricromene could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable."
08/01/2009 - "This study provides the first evidence that the new coumarin derivative cloricromene attenuates the degree of inflammation preserving the BRB in diabetic rats."
03/01/2003 - "This study provides the first evidence that cloricromene, a coumarin derivative, attenuates the degree of inflammation and tissue damage associated with EIU in rats."
12/01/1999 - "These data confirm that cloricromene exerts a notable inhibitory effect on PMN and may explain the activity of the compound, observed in vivo in several experimental models of ischaemia-reperfusion and shock."
01/14/1992 - "Cloricromene, a coumarine derivative, protects against lethal endotoxin shock in rats."
07/01/1989 - "In addition, cloricromene (5, 10, and 25 microM) added in vitro to peritoneal macrophages, collected from shocked rats, significantly enhanced their phagocytic activity depressed by shock."
07/01/1989 - "Cloricromene improves survival rate and peritoneal macrophage function in splanchnic artery occlusion shock in rats."
02/01/1991 - "The data suggest that cloricromene exerts beneficial effects in experimental hypovolemic shock, probably reversing myocardial failure."
04/01/1995 - "Administration of cloricromene (2 mg/kg i.v.), an inhibitor of TNF-alpha, significantly increased survival time (225 +/- 10 min), decreased serum levels of TNF-alpha and sE-selectin, reduced leukopenia and MPO activity in the ileum (0.035 +/- 0.003 U x 10(-3)/g tissue) and lung (0.3 +/- 0.005 U x 10(-3)/g tissue), improved the cardiovascular changes, and reduced the histological changes in the ileum and lung. "
01/14/1992 - "Cloricromene administration (0.5, 1 and 2 mg/kg i.v. 15 min after endotoxin) protected against LPS-induced lethality (100% survival rate 24 h after endotoxin challenge), reverted LPS-induced hypotension and leukopenia, and decreased TNF-alpha in both serum and macrophage supernatants. "
|5.||Prostatic Neoplasms (Prostate Cancer)
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Ethanol (Ethyl Alcohol)
|4.||DNA (Deoxyribonucleic Acid)
|7.||A-Form DNA (A-DNA)
|2.||Stapes Surgery (Stapedectomy)
|3.||Drug Therapy (Chemotherapy)